These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15746051)

  • 1. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
    Jahrsdorfer B; Mühlenhoff L; Blackwell SE; Wagner M; Poeck H; Hartmann E; Jox R; Giese T; Emmerich B; Endres S; Weiner GJ; Hartmann G
    Clin Cancer Res; 2005 Feb; 11(4):1490-9. PubMed ID: 15746051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
    Jahrsdörfer B; Wooldridge JE; Blackwell SE; Taylor CM; Griffith TS; Link BK; Weiner GJ
    J Leukoc Biol; 2005 Mar; 77(3):378-87. PubMed ID: 15582984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.
    Jahrsdörfer B; Hartmann G; Racila E; Jackson W; Mühlenhoff L; Meinhardt G; Endres S; Link BK; Krieg AM; Weiner GJ
    J Leukoc Biol; 2001 Jan; 69(1):81-8. PubMed ID: 11200072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides.
    Henault M; Lee LN; Evans GF; Zuckerman SH
    J Immunol Methods; 2005 May; 300(1-2):93-9. PubMed ID: 15894327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium.
    Pedersen G; Andresen L; Matthiessen MW; Rask-Madsen J; Brynskov J
    Clin Exp Immunol; 2005 Aug; 141(2):298-306. PubMed ID: 15996194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma.
    Buhé V; Guerrier T; Youinou P; Berthou C; Loisel S
    Ann N Y Acad Sci; 2009 Sep; 1173():858-64. PubMed ID: 19758238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
    Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
    Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
    J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice.
    Brummel R; Roberts TL; Stacey KJ; Lenert P
    Eur J Immunol; 2006 Jul; 36(7):1951-62. PubMed ID: 16791898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.
    Mason KA; Ariga H; Neal R; Valdecanas D; Hunter N; Krieg AM; Whisnant JK; Milas L
    Clin Cancer Res; 2005 Jan; 11(1):361-9. PubMed ID: 15671567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
    Ponzio NM; Cutro S; Hu J; Marzouk A; Marshall JD
    Int Immunopharmacol; 2006 Dec; 6(13-14):2057-68. PubMed ID: 17161362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis.
    Kikuchi K; Lian ZX; Kimura Y; Selmi C; Yang GX; Gordon SC; Invernizzi P; Podda M; Coppel RL; Ansari AA; Ikehara S; Miyakawa H; Gershwin ME
    J Autoimmun; 2005 Jun; 24(4):347-52. PubMed ID: 15878652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma.
    Agrelo R; Setien F; Espada J; Artiga MJ; Rodriguez M; Pérez-Rosado A; Sanchez-Aguilera A; Fraga MF; Piris MA; Esteller M
    J Clin Oncol; 2005 Jun; 23(17):3940-7. PubMed ID: 15867203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional TLR9 modulates bone marrow B cells from rheumatoid arthritis patients.
    Rudnicka W; Burakowski T; Warnawin E; Jastrzebska M; Bik M; Kontny E; Chorazy-Massalska M; Radzikowska A; Buler M; Maldyk P; Maslinski W
    Eur J Immunol; 2009 May; 39(5):1211-20. PubMed ID: 19384869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas.
    Paterson JC; Tedoldi S; Craxton A; Jones M; Hansmann ML; Collins G; Roberton H; Natkunam Y; Pileri S; Campo E; Clark EA; Mason DY; Marafioti T
    Haematologica; 2006 Jun; 91(6):772-80. PubMed ID: 16769579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.